146 related articles for article (PubMed ID: 24484617)
1. Serum protein acidic and rich in cysteine (SPARC) as a prognostic marker in soft tissue sarcomas.
Morgan SS; Nagle RB; Cranmer LD
Clin Sarcoma Res; 2014 Jan; 4(1):2. PubMed ID: 24484617
[TBL] [Abstract][Full Text] [Related]
2. Investigating the relationship between secreted protein acidic and rich in cysteine expression level and therapeutic efficacy of nab-paclitaxel: a meta-analysis.
Zhou X; Zhang L; Qierang C; Huang M; Yang X; Li L; Jiang J
Transl Cancer Res; 2021 Feb; 10(2):876-885. PubMed ID: 35116417
[TBL] [Abstract][Full Text] [Related]
3. SPARC-mediated long-term retention of nab-paclitaxel in pediatric sarcomas.
Pascual-Pasto G; Castillo-Ecija H; Unceta N; Aschero R; Resa-Pares C; Gómez-Caballero A; Vila-Ubach M; Muñoz-Aznar O; Suñol M; Burgueño V; Gomez-Gonzalez S; Sosnik A; Ibarra M; Schaiquevich P; de Álava E; Tirado OM; Mora J; Carcaboso AM
J Control Release; 2022 Feb; 342():81-92. PubMed ID: 34974029
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of weekly intravenous nanoparticle albumin-bound paclitaxel for non-small cell lung cancer patients who have failed at least two prior systemic treatments.
Duan J; Hao Y; Wan R; Yu S; Bai H; An T; Zhao J; Wang Z; Zhuo M; Wang J
Thorac Cancer; 2017 May; 8(3):138-146. PubMed ID: 28304139
[TBL] [Abstract][Full Text] [Related]
5. SPARC is a possible predictive marker for albumin-bound paclitaxel in non-small-cell lung cancer.
Komiya K; Nakamura T; Nakashima C; Takahashi K; Umeguchi H; Watanabe N; Sato A; Takeda Y; Kimura S; Sueoka-Aragane N
Onco Targets Ther; 2016; 9():6663-6668. PubMed ID: 27822069
[TBL] [Abstract][Full Text] [Related]
6. Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study.
Gong L; Mao W; Chen Q; Jiang Y; Fan Y
Cancer Chemother Pharmacol; 2019 Apr; 83(4):639-647. PubMed ID: 30643929
[TBL] [Abstract][Full Text] [Related]
7. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status.
Desai NP; Trieu V; Hwang LY; Wu R; Soon-Shiong P; Gradishar WJ
Anticancer Drugs; 2008 Oct; 19(9):899-909. PubMed ID: 18766004
[TBL] [Abstract][Full Text] [Related]
8. The pathological complete response and secreted protein acidic and rich in cysteine expression in patients with breast cancer receiving neoadjuvant nab-paclitaxel chemotherapy.
Nakazawa Y; Nakazawa S; Kurozumi S; Ogino M; Koibuchi Y; Odawara H; Oyama T; Horiguchi J; Fujii T; Shirabe K
Oncol Lett; 2020 Apr; 19(4):2705-2712. PubMed ID: 32218821
[TBL] [Abstract][Full Text] [Related]
9. Improved response to nab-paclitaxel compared with cremophor-solubilized paclitaxel is independent of secreted protein acidic and rich in cysteine expression in non-small cell lung cancer.
Shao H; Tang H; Salavaggione OE; Yu C; Hylander B; Tan W; Repasky E; Adjei AA; Dy GK
J Thorac Oncol; 2011 Jun; 6(6):998-1005. PubMed ID: 21532503
[TBL] [Abstract][Full Text] [Related]
10. Secreted protein acidic and rich in cysteine (SPARC) is associated with nasopharyngeal carcinoma metastasis and poor prognosis.
Wang HY; Li YY; Shao Q; Hou JH; Wang F; Cai MB; Zeng YX; Shao JY
J Transl Med; 2012 Feb; 10():27. PubMed ID: 22321704
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of nab-paclitaxel does not seem to be associated with SPARC expression in metastatic breast cancer.
Schneeweiss A; Seitz J; Smetanay K; Schuetz F; Jaeger D; Bachinger A; Zorn M; Sinn HP; Marmé F
Anticancer Res; 2014 Nov; 34(11):6609-15. PubMed ID: 25368265
[TBL] [Abstract][Full Text] [Related]
12. SPARC expression in patients with high-risk localized soft tissue sarcoma treated on a randomized phase II trial of neo/adjuvant chemotherapy.
Davis EJ; Zhao L; Lucas DR; Schuetze SM; Baker LH; Zalupski MM; Thomas D; Chugh R
BMC Cancer; 2016 Aug; 16():663. PubMed ID: 27544129
[TBL] [Abstract][Full Text] [Related]
13. Expression of secreted protein acidic and rich in cysteine is an independent prognostic indicator of a poor clinical outcome in oropharyngeal carcinoma patients.
Yoshida S; Wakisaka N; Kondo S; Moriyama-Kita M; Hirai N; Endo K; Tsuji A; Nakanishi Y; Murono S; Yoshizaki T
Acta Otolaryngol; 2016; 136(2):189-94. PubMed ID: 26523779
[TBL] [Abstract][Full Text] [Related]
14. Expression of peritumoral SPARC during distal cholangiocarcinoma progression and correlation with outcome.
Byrling J; Sasor A; Nilsson J; Said Hilmersson K; Andersson R; Andersson B
Scand J Gastroenterol; 2020 Jun; 55(6):725-731. PubMed ID: 32543919
[No Abstract] [Full Text] [Related]
15. Secreted protein acidic and rich in cysteine expression in human colorectal cancer predicts postoperative prognosis.
Liu QZ; Gao XH; Chang WJ; Wang HT; Wang H; Cao GW; Fu CG
Eur Rev Med Pharmacol Sci; 2015 May; 19(10):1803-11. PubMed ID: 26044224
[TBL] [Abstract][Full Text] [Related]
16. Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and translational trials.
Ormanns S; Haas M; Baechmann S; Altendorf-Hofmann A; Remold A; Quietzsch D; Clemens MR; Bentz M; Geissler M; Lambertz H; Kruger S; Kirchner T; Heinemann V; Boeck S
Br J Cancer; 2016 Dec; 115(12):1520-1529. PubMed ID: 27802454
[TBL] [Abstract][Full Text] [Related]
17. Stromal Caveolin-1 Is Associated With Response and Survival in a Phase II Trial of nab-Paclitaxel With Carboplatin for Advanced NSCLC Patients.
Bertino EM; Williams TM; Nana-Sinkam SP; Shilo K; Chatterjee M; Mo X; Rahmani M; Phillips GS; Villalona-Calero MA; Otterson GA
Clin Lung Cancer; 2015 Nov; 16(6):466-74. PubMed ID: 26123189
[TBL] [Abstract][Full Text] [Related]
18. Summary of expression of SPARC protein in cutaneous vascular neoplasms and mimickers.
Mauzo SH; Milton DR; Prieto VG; Torres-Cabala CA; Wang WL; Chakravarti N; Nagarajan P; Tetzlaff MT; Curry JL; Ivan D; Brown RE; Aung PP
Ann Diagn Pathol; 2018 Jun; 34():151-154. PubMed ID: 29660567
[TBL] [Abstract][Full Text] [Related]
19. SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer Patients.
Desai N; Trieu V; Damascelli B; Soon-Shiong P
Transl Oncol; 2009 May; 2(2):59-64. PubMed ID: 19412420
[TBL] [Abstract][Full Text] [Related]
20. A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma.
Kao SC; Kirschner MB; Cooper WA; Tran T; Burgers S; Wright C; Korse T; van den Broek D; Edelman J; Vallely M; McCaughan B; Pavlakis N; Clarke S; Molloy MP; van Zandwijk N; Reid G
Br J Cancer; 2016 Mar; 114(5):524-31. PubMed ID: 26889976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
